The North America Neurodiagnostics Market is positioned for robust expansion as neurodegenerative diseases rise and neurotechnology advances across the United States and Canada. The market is projected to increase from USD 2,420 million in 2025 to approximately USD 5,770 million by 2035, expanding at a CAGR of 8.7% from 2024 to 2035. Major players such as Nihon Kohden Corporation, Natus Medical Incorporated, and Compumedics have introduced a suite of advanced neurodiagnostic tools, further accelerating market growth.
The economic impact of tariffs on "North America Neurodiagnostics Market".
Market Growth Drivers
Rising prevalence of neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease in North America is significantly driving the demand for advanced neurodiagnostic solutions. For instance, Natus Medical Incorporated has expanded its EEG and EMG product lines, enabling faster diagnosis and intervention for neurological diseases. The aging population and increased awareness about early diagnosis amplify the adoption of these technologies across hospitals and specialized clinics.
Technological advancements and integration of AI in neurodiagnostic devices are also fueling market growth. Companies like NeuroPace Inc. have introduced artificial intelligence-powered EEG monitoring solutions which help clinicians identify abnormalities faster and support personalized treatment plans. The adoption of portable and real-time neuroimaging solutions, driven by continuous R&D and supportive regulatory frameworks, further supports overall market expansion.
Market Trends
The shift toward non-invasive diagnostic modalities is a dominant trend. Companies such as BrainScope Company Inc. offer portable, non-invasive devices for rapid assessment of brain injuries, gaining rapid adoption in emergency care and sports medicine. Healthcare facilities are increasingly investing in digital and wireless EEG/EMG devices, which streamline patient management and minimize hospital stays.
Adoption of remote neurological monitoring and tele-neurology solutions is increasing, particularly post-pandemic. Compumedics Limited, for example, has launched cloud-connected sleep and EEG monitoring systems, allowing clinicians to access diagnostic data and collaborate remotely. This trend not only enhances patient accessibility but also addresses the shortage of neurologists in rural and underserved regions.
Market Opportunity
The integration of neurodiagnostics with digital health platforms presents a lucrative opportunity. Companies like Philips Healthcare are exploring AI and IoT-enabled neurodevices for continuous remote patient monitoring, providing physicians with actionable insights and enhancing patient engagement.
Expansion into pediatric and mental health diagnostics offers further market penetration opportunities. Innovative products targeting early detection of neurological issues in children and psychiatric disorders are being developed by players like Medtronic, broadening the scope for neurodiagnostics applications.
North America Neurodiagnostics Market Revenue (USD Million), 2020-2035
The chart illustrates a steady and accelerating growth in North America's neurodiagnostics market revenue between 2020 and 2035. In 2020, the market was valued at around USD 1,350 million. Progressive adoption of advanced diagnostics, expanding applications, and wider insurance coverage have powered the industry's expansion, with revenues reaching an estimated USD 2,420 million by 2025 and anticipated to surpass USD 5,770 million by 2035. This upward trajectory highlights the growing emphasis on early neurological diagnosis, continuous advancements in medical imaging, and the entry of innovative AI-driven solutions that will shape the market's future.
North America Neurodiagnostics Market Share by Region (%), 2025
In 2025, the United States commands the majority of the North America Neurodiagnostics Market share, with approximately 72%, driven by high healthcare spending, rapid adoption of cutting-edge diagnostic technologies, and a strong presence of key market players. Canada follows with 18%, benefiting from increased investments in neurological research and improved healthcare infrastructure. Mexico accounts for 7% as improved healthcare accessibility supports growth, while the rest of North America holds 3%. The dominance of the U.S. in the regional landscape is expected to remain, given ongoing investments in R&D and early technology adoption.
Recent Developments
In April 2024, Compumedics Limited announced the launch of its wireless EEG/PSG monitoring platform across North America. This platform integrates cloud connectivity and advanced analytics for real-time neuro-monitoring, enhancing both hospital-based and at-home diagnostic capabilities. Early deployments demonstrated improved diagnostic turnaround and physician efficiency.
In March 2024, Natus Medical Incorporated received FDA clearance for its latest EMG/NCV diagnostic system, Natus UltraEMG, which is equipped with AI-powered signal analysis. This breakthrough allows clinicians to rapidly analyze nerve and muscle function, minimizing diagnostic errors and facilitating faster treatment decisions for neurological disorders.
In February 2024, BrainScope Company Inc. secured a partnership with several major U.S. hospital networks to deploy its handheld neurodiagnostic device, BrainScope One, for rapid concussion and mild traumatic brain injury assessment in emergency and sports medicine. The move aims to broaden the applicability of non-invasive, point-of-care neurodiagnostic services and improve patient outcomes region-wide.
Press Releases